Aethlon Medical (AEMD) said Monday that the first patient has been enrolled in an Australian clinical trial of its immunotherapeutic device Hemopurifier to treat patients with solid tumors.
The company said the trial will treat patients who have stable or progressive disease while receiving anti-PD-1 monotherapy, such as Keytruda or Opdivo.
Aethlon said the first patient will receive anti-PD-1 therapy within the next two months, when concentrations of extracellular vesicles and anti-tumor T cell activity will be measured.
Shares of Aethlon Medical were up 14% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。